One fourth of family medicine residencies "pharma free," says survey

Share this article:
Most US family medicine resident programs have limits on drug industry interaction with doctors, and a quarter shun doctor-company contacts altogether, said a survey by Georgetown University Medical Center and the American Medical Student Association.

The survey, begun in 2008, went out to directors or coordinators of all 460 accredited family medicine residency programs and drew responses from nearly two-thirds (62.2%). Around half said that they refused drug samples (52.1%) and industry gifts or food (48.6%). Sixty-eight percent said they did not allow industry-sponsored residency activities, and 44.1% denied industry access to students and residents at the family medicine center. Seventy-five residencies, 26.2% of those responding, were designated as “pharma-free.”

By comparison, in 1992, 90% of family medicine residencies allowed industry support, said Georgetown's Dr. Adriane Fugh-Berman, MD, who is also director of drug industry watchdog PharmedOut.

Industry-physician contacts have come in for withering criticism in recent years, particularly from academic medicine, and these results, though served up by a pair of institutions prominent among conflict-of-interest hawks, suggest that the criticism is having an impact.

“Family medicine is leading the way in closing the door on pharma” said Dr. Fugh-Berman in a statement. “Our survey allows for comments, so we know that some residency programs report recent changes in plans or practices to limit industry interaction. Although some faculty and some residents are opposed to these limits, it's clear that industry influence on family medicine residencies is waning.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...